Background-We assessed the contribution of endothelium-derived hyperpolarizing factors to resting and agoniststimulated vasodilator tone in health and disease. Tetraethylammonium chloride (TEA) was used to inhibit K
epoxyeicosatrienoic acids (EETs) from cytochrome P450 -dependent metabolism of arachidonic acid. Epoxyeicosatrienoic acids promote vasodilation by stimulating small and large calcium-dependent potassium channels (K ϩ Ca ) on endothelial cells, with subsequent membrane hyperpolarization and vasodilation. 13, 14 Agonists such as bradykinin stimulate endothelial G-protein-coupled receptors, provoking an increase in intracellular calcium, leading to opening of endothelial K ϩ Ca channels, and triggering the EDHF phenomena: synthesis of EETs, transmission of endothelial cell hyperpolarization to the vascular smooth muscle via gap junctions, and/or release of K ϩ from the endothelial cells, which in turn induces smooth muscle vasodilation by activating several other K ϩ channels. [15] [16] [17] Experimentally, a combination of apamin and charybdotoxin is used to specifically inhibit EDHF responses caused by K ϩ Ca activation, whereas in clinical studies, tetraethylammonium chloride (TEA) has been used as a K ϩ Ca channel inhibitor. 18 -20 The role of EETs as potential EDHFs has been studied in humans using azoles such as miconazole, fluconazole, and sulfaphenazole, which selectively inhibit epoxidation (EET generation) of arachidonic acid. 11, 13, 21 In this study, we measured the contribution of EDHF to resting vasomotor tone in the human forearm microcirculation in health and disease in both the presence and absence of NO, with the hypothesis that activation of K ϩ Ca channels and/or cytochrome P450 metabolites contributes to endothelium-dependent hyperpolarization, and that this contribution is altered in disease states with endothelial dysfunction. Second, we explored the contribution of EDHF to endothelium-dependent vasodilation in both the presence and absence of NO, with the hypothesis that activation of K ϩ Ca channels in response to acetylcholine and bradykinin contributes to forearm microvascular vasodilation and that this contribution is altered in hypercholesterolemic compared with healthy circulation.
Methods

Subjects
Healthy and nonhypertensive subjects with multiple risk factors who were between 21 and 60 years of age were enrolled in 4 separate protocols that explored the contribution of EDHF to resting tone in healthy subjects and those with cardiovascular risk factors that included hypercholesterolemia and diabetes mellitus, the contribution of EETs to resting tone, the differential contribution of EETs and K ϩ Ca channel activation to resting tone, and the contribution of EDHF to agonist-stimulated vasodilation in healthy and hypercholesterolemic subjects. All subjects were nonsmokers and free of hypertension, cardiovascular disease, and systemic disorders. Subjects with risk factors (protocols 1 through 3) were older and had similar blood pressures; a greater body mass index (BMI); higher fasting levels of glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides; and lower levels of highdensity lipoprotein cholesterol compared with healthy subjects (Table). Subjects in protocol 4 had similar significant differences in cholesterol and its subfractions compared with healthy subjects, but were matched for all other factors. All healthy subjects and those with hypercholesterolemia were not taking any medications; diabetics discontinued their insulin or metformin the night before, and 1 subject on sulfonylureas discontinued it before enrollment. Pregnant women were excluded. The study was approved by the Emory University Institutional Review Board, and all subjects provided informed consent.
Measurement of Forearm Blood Flow
Measurements were performed in subjects after an overnight fast in a quiet temperature-controlled (22°C to 24°C) room. Subjects refrained from exercise, alcohol, and caffeine for at least 24 hours beforehand. After insertion of an intrabrachial arterial cannula for arterial pressure monitoring and delivery of drug infusions, subjects received oral aspirin (975 mg) to inhibit prostacyclin synthesis at least 1 hour before the study. 22 Simultaneous forearm blood flow (FBF) measurements were obtained in both arms with a dual-channel venous occlusion strain gauge plethysmograph (model EC6, DE Hokanson, Bellevue, WA) as described previously. 2 Flow measurements were recorded for Ϸ7 seconds every 15 seconds up to 8 times and, a mean FBF value in milliliters per minute per 100 mL was computed. Forearm vascular resistance was calculated as the mean arterial pressure divided by FBF and is expressed as millimeters of mercury per 1 mL ⅐ min Ϫ1 ⅐ 100 mL Ϫ1 .
Protocol 1: Contribution of Nitric Oxide and K
؉ Ca
Channel Activation to Resting Vasodilator Tone
All agents were administered intra-arterially after resting measurements were made during saline infusion (2.5 mL/min). In 37 healthy and 25 subjects with risk factors, FBF was measured during inhibition of NO synthesis during a 5-minute infusion of N G -monomethyl-L-arginine (L-NMMA; Clinalfa, Laufelfingen, Switzerland) given at 8 mol/min, which was previously shown to attenuate resting and agonist-stimulated FBF. 2 While L-NMMA was continued, intra-arterial TEA (Clinalfa) at 1 mg/min was infused for 5 minutes to investigate the effect of combined blockade of NO and K ϩ Ca channels on resting vessel tone. When given at 0.25 to 1 mg/min, TEA selectively inhibits K ϩ Ca channels but reduces FBF with bradykinin only at 1 mg/min (Ͻ0.6mol/min). 6, 12, 19, 20 In separate experiments in 41 healthy subjects and 32 subjects with risk factors, TEA was infused first to investigate the effects of blockade of K ϩ Ca channels without prior NO inhibition. This was followed by In 19 healthy subjects, the differential contribution of cytochrome P450 -derived epoxides and K ϩ Ca channel activation to resting vasodilator tone was investigated. Forearm blood flow was measured at rest and after infusion of fluconazole (0.4 mol/min) for 5 minutes and finally after combined infusions of fluconazole and TEA at 1 mg/min for 5 minutes.
Protocol 4: Contribution of K ؉
Ca Channel Activation to Bradykinin and Acetylcholine-Mediated Vasodilation in Healthy and Hypercholesterolemic Vasculature
Fifty-four healthy subjects and 44 subjects with hypercholesterolemia participated in this protocol. In 27 healthy and 24 hypercholesterolemic subjects, FBF was measured at rest and after intra-arterial infusion of the endothelium-dependent vasodilators bradykinin (Clinalfa) at 100, 200, and 400 ng/min or acetylcholine (Novartis, East Hanover, NJ) at 7.5, 15, and 30 g/min, followed by intra-arterial infusion of the endothelium-independent vasodilator sodium nitroprusside at 1.6 and 3.2 mg/min for 5 minutes each ( Figure 1 ). This was followed by infusion of L-NMMA (8 mol/min) for 5 minutes; then, escalating doses of either bradykinin or acetylcholine were repeated. After a 30-minute rest period, TEA 1 mg/min was begun for 5 minutes, and while L-NMMA and TEA infusions were continued, bradykinin or acetylcholine infusions and sodium nitroprusside infusions were repeated. This protocol enabled measurement of the contribution of NO and combined NO and K ϩ Ca channel activation to endothelium-dependent and -independent vasodilation.
Finally, to investigate the effect of inhibition of K ϩ Ca channels on agonist-mediated vasodilation without prior blockade of NO, we studied another 27 healthy and 20 hypercholesterolemic subjects. After measurement of FBF during bradykinin or acetylcholine infusions, TEA was infused followed by repeat infusions of bradykinin or acetylcholine. Finally, combined infusions of TEA and L-NMMA were given, followed by repeat infusions of bradykinin or acetylcholine and sodium nitroprusside ( Figure 1 ). This enabled assessment of the contribution of K ϩ Ca channel activation without blockade of NO to agonist-stimulated endothelium-dependent and -independent vasodilation.
Statistical Analysis
In protocols 1 through 3, to assess the treatment effect of TEA, L-NMMA, fluconazole, and their combination within healthy and risk factor groups, a paired t test was used to compare single blockade with baseline and combined blockade with single blockade. Then, to compare the magnitude of treatment effects between the healthy and risk factor groups (in protocol 1 and 2), an unpaired t test was used to compare the changes in single blockade on baseline and the changes of combined blockade on single blockade. Multivariable regression analysis was performed by fitting regression models with each of the factors in the Table ( age, sex, body mass index, blood pressure, and glucose and lipid levels) for possible confounding effects. The Pearson correlation coefficient was used to assess the correlation between the percentage changes in FBF with L-NMMA versus TEA.
In protocol 4, the treatment effects in FBF and forearm vascular resistance were assessed within subjects for baseline versus single blockade versus combined blockade by repeated-measures ANOVA with treatment levels as the main effect. Then, the magnitude of the treatment effects was compared between healthy and hypercholesterolemic subjects by repeated-measures ANOVA with health status groups as the main effect. Possible confounding effects were controlled for age, sex, blood pressure, body mass index, and LDL levels in a stepwise fashion. Reported P values are based on main effects.
Results are presented as meanϮSD in the text and as least-square means and SEs in the figures. The Bonferroni method was used for adjustment for multiple comparisons for comparing baseline, TEA, L-NMMA, fluconazole, and combinations. Reported P values are values before adjustment. 
Results
Relative Contribution of K ؉
Ca Channel Activation and Nitric Oxide to Resting Vasodilator Tone
In protocol 1, TEA infusion produced vasoconstriction; resting FBF decreased by 18Ϯ16% (PϽ0.0001) in healthy subjects and by 24Ϯ13% (PϽ0.0001) in those with risk factors, indicating a significant contribution of K ϩ Ca channel activation to resting microvascular vasodilator tone. The magnitude of vasoconstriction with TEA was lower in healthy subjects compared with those with risk factors (Pϭ0.04). Addition of L-NMMA to TEA further reduced FBF in both groups (Figure 2A , 2B, 2E, and 2F).
When L-NMMA was infused first, resting FBF decreased by 29Ϯ17% (PϽ0.0001) in healthy subjects and by 23Ϯ15% (PϽ0.0001) in those with risk factors. Vasoconstriction with L-NMMA was greater in healthy subjects than in those with risk factors (Pϭ0.04). Addition of TEA to L-NMMA further reduced FBF in both groups, indicating a significant contribution of K ϩ Ca channel activation to resting vasodilator tone, even after NO blockade ( Figure 2C, 2D, 2G , and 2H). Thus, there was a greater contribution of K ϩ Ca channel activation and a lower contribution of NO to resting microvascular vasodilator tone in those with risk factors compared with healthy subjects. Moreover, in the entire population, there was an inverse relationship between the constrictor responses to L-NMMA and TEA, indicating that reduced NO bioavailability is accompanied by higher K ϩ Ca channel activity and vice versa (Figure 3) . The reduction in FBF after dual blockade was similar in healthy subjects and those with risk factors (38Ϯ17% versus 39Ϯ17% reduction in FBF; Pϭ0.78).
Multivariate analysis was performed to determine whether demographic/risk factors, including age, sex, body mass index, total, LDL and high-density lipoprotein cholesterol, glucose, and systolic blood pressure, were determinants of the flow responses to L-NMMA and TEA. The multivariate determinants of the constrictor response with L-NMMA were LDL cholesterol (Pϭ0.0002), total cholesterol (Pϭ0.0003), systolic blood pressure (Pϭ0.0016), and fasting glucose (Pϭ0.003), and multivariate determinants of the vasoconstrictor response to TEA were LDL levels (Pϭ0.05) and the L-NMMA response (Pϭ0.006).
Contribution of Cytochrome P450 Metabolites to Resting Vasodilator Tone
In protocol 2, infusion of fluconazole decreased FBF by 13Ϯ16% (Pϭ0.001) in healthy subjects and by 17Ϯ13% (Pϭ0.04) in those with risk factors, indicating a significant contribution of cytochrome P450 metabolites to resting vasodilator tone. Infusion of L-NMMA after fluconazole reduced FBF by an additional 25Ϯ13% (Pϭ0.02) in healthy subjects, changes that were similar to those observed in subjects with risk factors. When L-NMMA was infused before fluconazole, resting FBF decreased by 37Ϯ12% (Pϭ0.002) in healthy subjects and by 31Ϯ14% (Pϭ0.009) in subjects with risk factors. In the presence of L-NMMA, infusion of fluconazole further reduced FBF by 26Ϯ22% (Pϭ0.03) in both groups. Reduction in FBF with fluconazole tended to be greater after inhibition of NO than when given in the presence of NO (26Ϯ22% versus 13Ϯ16% reduction in FBF; Pϭ0.07).
Comparative Contribution of Cytochrome P450 Metabolites and K
؉
Ca Channel Activation
To assess the relative contribution of the 2 potential hyperpolarization mechanisms (cytochrome P450 metabolites and K ϩ Ca channel activation) to resting vasodilator tone, individual and combined blockade with fluconazole and TEA was studied in protocol 3. In healthy subjects, fluconazole infusion reduced FBF by 12Ϯ13% (Pϭ0.002), and the addition of TEA further reduced FBF by 22Ϯ23% (Pϭ0.01), indicating that hyperpolarizing factor(s) beyond cytochrome P450 metabolites are activating K ϩ Ca channels at rest ( Figure 4A and 4B).
Contribution of K ؉
Ca Channel Activation and Nitric Oxide to Bradykinin Responses
Studies were performed in healthy and hypercholesterolemic subjects in protocol 4. Bradykinin infusion resulted in doserelated forearm vasodilation that was similar in magnitude in healthy (nϭ29) and hypercholesterolemic (nϭ26) subjects (both PϽ0.0001; Figure 5 ). We found that L-NMMA lowered FBF by 17% (Pϭ0.0003) in healthy subjects ( Figure 5A and 5C) and by 33% (PϽ0.0001) in hypercholesterolemic subjects ( Figure 5E and 5G). Bradykinin-mediated vasodilation was also attenuated by TEA in the absence of L-NMMA in both groups. Thus, in both groups, FBF was 25%, PϽ0.0001 lower ( Figure 5B , 5D, 5F, and 5H) after TEA. Bradykinin-induced vasodilation was further attenuated after the addition of L-NMMA to TEA in both groups.
Contribution of K ؉
Ca Channel Activation and Nitric Oxide to Acetylcholine Responses
Acetylcholine produced dose-related forearm vasodilation that was significantly lower in hypercholesterolemic compared with healthy subjects (Pϭ0.05), as previously described. 2 We found that L-NMMA attenuated the acetylcholine-stimulated FBF increase by 28% (Pϭ0.0006; Figure 6A and 6C) in healthy subjects and by 26% (Pϭ0.0002) in those with hypercholesterolemia ( Figure 6E and 6G) . Addition of TEA to L-NMMA produced no further inhibition of acetylcholine-induced vasodilation (Pϭ0.19) in healthy subjects ( Figure 6A and 6C ), but in those with hypercholesterolemia, there was a 10% reduction in FBF (Pϭ0.09) and a 21% increase in forearm vascular resistance (Pϭ0.04; Figure 6E and 6G).
Infusion of TEA alone did not change acetylcholinemediated vasodilation in healthy subjects (Pϭ0.97; Figure 6B and 6D). In contrast, in hypercholesterolemic subjects, acetylcholine-stimulated FBF was lowered by 18% (Pϭ0.04; Figure 6F and 6H). The addition of L-NMMA to TEA significantly attenuated acetylcholine-stimulated vasodilation in both groups. Thus, unlike bradykinin, there was no contribution of K ϩ Ca channel activation to acetylcholinemediated vasodilation in healthy subjects; however, there was a significant K ϩ Ca channel activation with acetylcholine in hypercholesterolemia. Moreover, the magnitude of constriction with NO blockade in the presence of K ϩ Ca channel blockade was lower in the hypercholesterolemic group compared with healthy subjects (9% versus 37%; Pϭ0.023).
Contribution of K ؉
Ca Channel Activation and Nitric Oxide to Sodium Nitroprusside Responses
Vasodilation with sodium nitroprusside was similar in healthy and hypercholesterolemic subjects (FBF at the peak dose, 10.4Ϯ4 versus 10.9Ϯ5 mL ⅐ min Ϫ1 ⅐ 100 mL
Ϫ1
, respectively; Pϭ0.63). Importantly, infusions of L-NMMA and TEA did not alter the vasodilator responses to sodium nitroprusside in either group (Figure 7) .
Throughout each experiment, there was no change in mean arterial blood pressure or FBF in the control, noninfused arm. G -monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA) in healthy (nϭ17) subjects. FBF (B) and vascular resistance (D) during infusion of bradykinin alone and after initial infusion of TEA, followed by combined TEA and L-NMMA infusions in healthy (nϭ12) subjects. FBF (E) and vascular resistance (G) in response to increasing doses of bradykinin alone, after initial infusion of L-NMMA, and combined blockade with L-NMMA and TEA in hypercholesterolemic (nϭ16) subjects. FBF (F) and vascular resistance (H) during infusion of bradykinin alone and after initial infusion of TEA, followed by combined TEA and L-NMMA infusions in hypercholesterolemic (nϭ10) subjects. Data presented as meanϮSEM.
Discussion
Here, we report first that EDHFs contribute to resting vasodilator tone in vivo via activation of K ϩ Ca channels. The contribution of NO to resting tone in the human forearm microcirculation is greater compared with activation of K ϩ Ca channels in healthy subjects, but in those with multiple risk factors, K ϩ Ca channel activation contributes equally as much as NO. Thus, there is an inverse relationship between tonic basal NO and EDHF activities. Second, a candidate EDHF, cytochrome P450 -derived EET, also contributes to resting vasodilator tone in the healthy microcirculation, and in the presence of NO deficiency, EET-mediated vasodilation is upregulated. Third, sources other than EETs activate K ϩ Ca channels because there was additional constriction with TEA after fluconazole. Fourth, bradykinin-stimulated vasodilation is mediated by both NO and activation of K ϩ Ca channels in healthy and hypercholesterolemic subjects. Finally, in contrast to bradykinin, K ϩ Ca channel activation does not contribute to acetylcholine-stimulated vasodilation in health, but in hypercholesterolemia, there is reduced NO release and a significant contribution of K ϩ Ca channel activation to the acetylcholine response. Thus, enhanced EDHF activity in conditions of NO deficiency contributes to maintenance of resting and agonist-stimulated vasodilation.
Contribution of Nitric Oxide and K
؉
Ca Channel Activation to Resting Microcirculatory Tone
We confirm previous findings that basal NO contributes substantially to vasodilator tone of the microcirculation. 7, 21 For the first time, we demonstrate that the presence of multiple risk factors, including raised LDL cholesterol, hy- perglycemia, and higher systolic blood pressure, even within the normal range, are all associated with reduced basal NO activity in the microcirculation, findings previously described in conductance vessels and with agonists such as acetylcholine. 4, 23, 24 In our study, the most important determinants of TEA responses were serum LDL and the amount of basal NO activity.
Previous controversies regarding the contribution of EDHF in the human vasculature resulted largely from the use of nonspecific antagonists for the inhibition of endogenous EDHFs. 6, 12 We found that activation of K ϩ Ca channels plays an important role in the maintenance of resting vasodilator tone, contributes less than NO in healthy subjects, but contributes as much as NO in those with multiple cardiovascular risk factors. Thus, in the presence of endothelial dysfunction, typified by decreased NO activity, preservation of residual endothelium-dependent vasodilation is via K ϩ Ca channel signaling in humans (Figure 3 ), a finding previously demonstrated in experimental animals. 13, 25 Contribution of Endothelium-Derived Cytochrome P450 Metabolites to Basal Tone Endothelium-derived cytochrome P450 metabolites of arachidonic acid hyperpolarize membranes primarily by activating the K ϩ Ca channels, although the identity of the specific EETs remains controversial. 26 -28 In addition, EETs may act in an autocrine fashion, promoting amplification of endothelial cell hyperpolarization, the initial step in the EDHF phenomenon. Using fluconazole, we have demonstrated an important contribution of cytochrome P450 -dependent EET synthesis to microvascular dilator tone in vivo in both the presence and absence of NO and in both individuals with healthy vasculature and those with risk factors. We found no difference in the magnitude of inhibition with fluconazole between healthy subjects and those with risk factors, whereas greater K ϩ Ca channel activation was present in the latter. This suggests that EDHFs other than EETs that activate K ϩ Ca channels are upregulated in subjects with risk factors. Previous studies investigating the contribution of EETs to resting tone have been contradictory, partly because of differences in inhibitors used or the small numbers of subjects studied. For example, sulfaphenazole and miconazole had no effect on resting blood flow in small groups of subjects. Moreover, both decreases in and no change in conductance vessel diameter and flow have been reported previously with cytochrome P450 inhibition. 11, 21, 29, 30 Other studies have demonstrated a significant contribution of cytochrome P450 -derived metabolites to resting vasodilator tone in coronary and renal arteries from several species and, in the human, mammary artery, forearm vasculature, and skeletal muscle circulations. 31, 32 Because inhibition of EETs had a lesser effect than inhibition of K ϩ Ca channels on resting tone and because further inhibition of vasodilator tone was observed after TEA, it is clear that sources of K ϩ Ca channel activation other than EETs are contributing to the EDHF phenomenon, which in experimental studies has been attributed to hydrogen peroxide, gap junctions, or elevations in K ϩ release from the endothelial cells. 13, 17, 18 Another possibility is that stores of EETs in the endothelial layer may be released once the cell is activated, independently of cytochrome P450 epoxygenases. 33 
Contribution of Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor to Bradykinin-and Acetylcholine-Mediated Vasodilation
Having confirmed our previous findings that the response to bradykinin is similar between healthy and hypercholesterolemic subjects, we now demonstrate that both K ϩ Ca channel activation and NO contribute to the bradykinin response. 2 In contrast, the response to acetylcholine is diminished in hypercholesterolemia, which in experimental studies is believed to be associated with defects in NO bioavailability, no change in prostaglandins, and increased contribution of EDHF. 2,25,34 -36 We now demonstrate not only that there is no contribution of K ϩ Ca channel activation to acetylcholinemediated vasodilation in healthy subjects but also that there is increased signaling via K ϩ Ca channel activation in hypercholesterolemia. Similar findings of increased contribution of cytochrome P450 2C9 products with acetylcholine have been reported in hypertension. 37 
Limitations
Our findings are limited to the forearm microcirculation; thus, other vascular beds, including conductance arteries, warrant further investigation. Nevertheless, it is known that the contribution of EDHF is smaller in conductance vessels than in the microvessels. 13, 14, 38 Second, L-NMMA, TEA, and fluconazole are competitive inhibitors and may not com- pletely inhibit NO, K ϩ Ca channels, and cytochrome P450 pathways and thus may underestimate the importance of these mediators in vivo. Third, other endothelium-derived vasoactive mediators may play a compensatory role after blockade of NO, K ϩ Ca channels, and cytochrome P450 epoxygenase and need to be investigated. Finally, our investigations were conducted on a background of cyclooxygenase inhibition. Although we have previously demonstrated that vasodilator prostanoids contribute to resting vasodilator tone, we found that cyclooxygenase products did not contribute to the endothelial dysfunction of hypertensive or hypercholesterolemic patients. 36 
Implications
Because of the known protective role of NO on the vessel wall that not only promotes blood flow, but also impedes thrombosis and atherosclerosis, research has focused predominantly on developing strategies that enhance NO bioavailability. Understanding the pathophysiology of endothelial dysfunction beyond NO, in particular with respect to EDHF in these disease states, is crucial in both understanding the pathophysiology of atherosclerosis and developing novel therapies. 
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